How this Peninsula startup — with a hand from Genentech’s first scientist — is climbing toward heart disease cures


A uniquely California story — from naming to funding — Tenaya Therapeutics scores $92 million Series B round to pursue multiple ways to fix heart diseases.

Previous Beverly-based life sciences firm wants to tackle possible 'under-reporting' of EEE
Next Struggling Houston health care co. closes corporate HQ, lays off employees